4/A//SEC Filing
BERMAN DENNIS N 4/A
Accession 0000950170-25-023572
CIK 0001750149other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:06 PM ET
Size
15.7 KB
Accession
0000950170-25-023572
Insider Transaction Report
Form 4/AAmended
BERMAN DENNIS N
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-01-21+21,854→ 21,854 totalExercise: $1.26Exp: 2026-08-31→ Common Stock (21,854 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+3,780→ 3,780 totalExercise: $1.26Exp: 2028-06-25→ Common Stock (3,780 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+6,667→ 6,667 totalExercise: $1.26Exp: 2029-06-24→ Common Stock (6,667 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+6,667→ 6,667 totalExercise: $1.26Exp: 2030-06-30→ Common Stock (6,667 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+30,000→ 30,000 totalExercise: $1.26Exp: 2031-07-16→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.
- [F2]The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
- [F3]The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F4]This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Documents
Issuer
Inhibikase Therapeutics, Inc.
CIK 0001750149
Entity typeother
Related Parties
1- filerCIK 0001273858
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 8:06 PM ET
- Size
- 15.7 KB